Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by PAX Financial Group LLC

PAX Financial Group LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 42.7% during the first quarter, Holdings Channel reports. The firm owned 745 shares of the biopharmaceutical company’s stock after acquiring an additional 223 shares during the period. PAX Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $520,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Core Alternative Capital grew its holdings in Regeneron Pharmaceuticals by 800.0% during the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 32 shares during the period. Benjamin Edwards Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $33,000. Delos Wealth Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $33,000. Byrne Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $34,000. Finally, Addison Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 220.0% during the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 33 shares during the period. 83.83% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $620.91, for a total transaction of $9,313,650.00. Following the completion of the sale, the director now owns 1,872 shares of the company’s stock, valued at $1,162,343.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the firm’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $587.76, for a total transaction of $646,536.00. Following the completion of the sale, the executive vice president now owns 19,644 shares of the company’s stock, valued at $11,545,957.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $620.91, for a total value of $9,313,650.00. Following the sale, the director now directly owns 1,872 shares of the company’s stock, valued at approximately $1,162,343.52. The disclosure for this sale can be found here. Insiders sold a total of 51,435 shares of company stock valued at $31,663,304 over the last quarter. 8.99% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $648.70 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $538.01 and a one year high of $747.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12. The stock has a market cap of $70.71 billion, a PE ratio of 12.95, a P/E/G ratio of 2.24 and a beta of 0.29. The stock has a 50 day moving average price of $597.24 and a 200 day moving average price of $637.08.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same period in the prior year, the business posted $27.97 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was down 44.4% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Jefferies Financial Group downgraded Regeneron Pharmaceuticals to a “sell” rating and set a $536.00 price target on the stock. in a research report on Friday, June 17th. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an “overweight” rating on the stock in a research report on Friday, June 3rd. StockNews.com downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Argus increased their price target on Regeneron Pharmaceuticals from $680.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday, May 31st. Finally, Cowen increased their price target on Regeneron Pharmaceuticals to $655.00 in a research report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $698.35.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.